LIMIT Early Adiposity Rebound in Children

Overview

Childhood obesity is a strong predictor of adult obesity with health and economic consequences for the individual and society. Adiposity rebound (AR) is a rise in the Body Mass Index occurring between 3-7 years. Early adiposity rebound (EAR) occurs at a median age of 2 years and is a risk factor for later obesity. Events happening in "the first 1,000 days" play a role in obesity development. One of the key elements in this crucial time window is the gut microbiome, a highly dynamic organ that is sensitive to environmental exposure being linked to obesity development. Prenatal (dietary/lifestyle maternal factors and environmental exposure) and postnatal determinants (the type of feeding, sleep patterns, speed of growth) and environmental obesogenic pollutants may influence the infant microbial colonization, thus increasing the risk of EAR onset. LIMIT will holistically identify the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with AR vs EAR, driving new mechanistic insights to create an EAR predictive model. The study will evaluate a group of 150 mother-infant pairs, during the first four years of life at different follow-up.

Full Title of Study: “LIMIT (LIfestyle and Microbiome InTeraction) Early Adiposity Rebound in Children”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2025

Interventions

  • Other: Evaluation of microbiome and maternal/infant lifestyle
    • Identification of the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with adiposity rebound vs children with early adiposity rebound.

Arms, Groups and Cohorts

  • Dyads
    • Mother/infant pairs will be evaluated for anthropometric parameters, prenatal (dietary/lifestyle maternal factors)/postnatal determinants (type of feeding, sleep patterns, speed of growth) before discharge and after different follow-up after birth. Infant urinary and stool samples will be collected and stored. The infant adiposity rebound will be monitored.

Clinical Trial Outcome Measures

Primary Measures

  • Infant’s intestinal microbiome assessment – relative abundance
    • Time Frame: 0-48 month
    • To investigate the infant’s intestinal microbiome development (0-48 months) by identifying the relative abundance of the dominant microbes.
  • Infant’s intestinal microbiome assessment – microbial diversity
    • Time Frame: 0-48 month
    • To investigate the infant’s intestinal microbiome development (0-48 months) by assessing the microbial diversity.
  • Infant’s intestinal microbiome assessment – inter-individual variation
    • Time Frame: 0-48 month
    • To investigate the infant’s intestinal microbiome development (0-48 months) by assessing the inter-individual variation.

Secondary Measures

  • Adiposity rebound identification
    • Time Frame: 0-48 month
    • To identify adiposity rebound (AR) in children, discriminating between early AR and normal AR.
  • Infant intestinal microbiome and pre-gestational weight status
    • Time Frame: 0-48 month
    • To identify the longitudinal interplay between infant intestinal microbiome and pre-gestational weight status in children showing early adiposity rebound and in those showing normal adiposity rebound. In brief, maternal height (cm) and pre-pregnancy weight will be registered to calculate pre-gestational body mass index (BMI, Kg/m2).
  • Infant intestinal microbiome and maternal weight gain
    • Time Frame: 0-48 month
    • To identify the longitudinal interplay between infant intestinal microbiome and maternal weight gain (Kg) during pregnancy in children showing early adiposity rebound and in those showing normal adiposity rebound.
  • Infant intestinal microbiome and maternal dietary habits
    • Time Frame: 0-48 month
    • To identify the longitudinal interplay between infant intestinal microbiome, and maternal dietary habits in children showing early adiposity rebound and in those showing normal adiposity rebound. Dietary habits will be evaluated by using a previously validated questionnaire.
  • Infant intestinal microbiome and maternal physical activity
    • Time Frame: 0-48 month
    • To identify the longitudinal interplay between infant intestinal microbiome and maternal physical activity during pregnancy in children showing early adiposity rebound and in those showing normal adiposity rebound. Physical activity will be evaluated by using a previously validated questionnaire.
  • Infant intestinal microbiome and mode of delivery
    • Time Frame: 0-48 month
    • To identify the longitudinal interplay between infant intestinal microbiome and mode of delivery (vaginal delivery vs. caesarean section delivery) in children showing early adiposity rebound and in those showing normal adiposity rebound.
  • Infant intestinal microbiome and lactation
    • Time Frame: 0-48 month
    • To identify the longitudinal interplay between infant intestinal microbiome and lactation (breastfeeding vs. formula feeding) in children showing early adiposity rebound and in those showing normal adiposity rebound.
  • Infant intestinal microbiome and maternal endocrine disruptors chemicals (EDCs) exposure
    • Time Frame: 0-48 month
    • To identify the longitudinal interplay between infant intestinal microbiome and maternal EDCs exposure (e.g. BPA, phthalates) in children showing early adiposity rebound and in those showing normal adiposity rebound.
  • Infant intestinal microbiome and dietary habits
    • Time Frame: 0-48 month
    • To identify the longitudinal interplay between infant intestinal microbiome and dietary habits in children showing early adiposity rebound and in those showing normal adiposity rebound. Infant dietary habits will be evaluated by using a previously validated questionnaire.
  • Infant intestinal microbiome and infant sleeping habits
    • Time Frame: 0-48 month
    • To identify the longitudinal interplay between infant intestinal microbiome and sleeping habits, in children showing early adiposity rebound and in those showing normal adiposity rebound.
  • Predictive model
    • Time Frame: 48-60 month
    • To develop a predictive model for the early adiposity rebound risk taking into consideration all maternal and infant factors previously evaluated.

Participating in This Clinical Trial

Inclusion Criteria

i) Infants of both sexes born to vaginal/caesarean delivery; ii) Gestational age: 37-42 weeks; iii) Italian-speaking parent; iv) 7 Ability of the parent/guardian to give informed consent; v) Ability of the mother to answer questionnaires. Exclusion Criteria:

i) Infants with genetic/congenital diseases; ii) Infants selected for another clinical study; iii) Infants hospitalized immediately after birth; iv) Presence of gestational diabetes; v) Presence of hyperthyroidism during pregnancy; vi) Parents refusing to sign the informed consent.

Gender Eligibility: All

Minimum Age: 1 Day

Maximum Age: 48 Months

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Pavia
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Rachele De Giuseppe, PhD, Principal Investigator, University of Pavia
  • Overall Contact(s)
    • Ilaria Di Napoli, Dr, +390382987536, ilaria.dinapoli@unipv.it

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.